At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SVRA Savara Inc
Pre-Mkt 10-27 05:16:44 EDT
4.52
+0.30
+7.11%
High4.54Low4.22Vol3.45M
Open4.34D1 Closing4.22Amplitude7.68%
Mkt Cap925.05MTradable Cap895.86MTotal Shares204.66M
T/O15.11MT/O Rate1.74%Tradable Shares198.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mastek Ltd Says Sept-Quarter Consol Net Profit 1.06 Billion Rupees
Reuters  ·  10-23
Mastek Ltd Says Sept-Quarter Consol Net Profit 1.06 Billion Rupees
Savara’s Molgramostim Improves Gas Transfer in Exploratory aPAP Trial Analysis
Reuters  ·  10-22
Savara’s Molgramostim Improves Gas Transfer in Exploratory aPAP Trial Analysis
Savara to Present New Impala Trial Analysis of Molgramostim in aPAP at CHEST 2026
Reuters  ·  10-13
Savara to Present New Impala Trial Analysis of Molgramostim in aPAP at CHEST 2026
Savara Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $12
THOMSON REUTERS  ·  10-07
Savara Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $12
Top Premarket Gainers
MT Newswires Live  ·  10-06
Top Premarket Gainers
Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)
TIPRANKS  ·  08-26
Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)
Savara announces presentations of Results from Phase 3 trial of Molgramostim
TIPRANKS  ·  08-25
Savara announces presentations of Results from Phase 3 trial of Molgramostim
Savara to Present Phase 3 Impala-2 Molgramostim Data in Autoimmune Pulmonary Alveolar Proteinosis at ERS 2026
Reuters  ·  08-25
Savara to Present Phase 3 Impala-2 Molgramostim Data in Autoimmune Pulmonary Alveolar Proteinosis at ERS 2026
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2026
THOMSON REUTERS  ·  08-25
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2026
Savara Grants New Hires Options for 74,500 Shares at $5.37, RSUs for 64,500 Shares
Reuters  ·  08-21
Savara Grants New Hires Options for 74,500 Shares at $5.37, RSUs for 64,500 Shares
Savara Merilis Presentasi Korporasi Tentang Penyakit Paru Langka Autoimmune PAP Dan Kandidat Terapi Inhalasi Molbreevi
Reuters  ·  08-12
Savara Merilis Presentasi Korporasi Tentang Penyakit Paru Langka Autoimmune PAP Dan Kandidat Terapi Inhalasi Molbreevi
Savara Q2 EPS $(0.16) Misses $(0.14) Estimate
Benzinga Earnings  ·  08-12
Savara Q2 EPS $(0.16) Misses $(0.14) Estimate
Savara Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Savara Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Savara Q2 Loss Widens as Operating Expenses Rise
Reuters  ·  08-12
Savara Q2 Loss Widens as Operating Expenses Rise
Savara Rugi Bersih Q2 FY26 Melebar 32,3% Ke USD 40,2 Juta
Reuters  ·  08-12
Savara Rugi Bersih Q2 FY26 Melebar 32,3% Ke USD 40,2 Juta
Savara Q2 Net Income USD -40.228 Million
Reuters  ·  08-12
Savara Q2 Net Income USD -40.228 Million
Savara - European and Australian Patent Offices Grant Molbreevi Patents Until March 2041
THOMSON REUTERS  ·  08-12
Savara - European and Australian Patent Offices Grant Molbreevi Patents Until March 2041
Savara - Molbreevi MAAS Under Review by Ema and U.k's Mhra; Decisions Expected Q1 2027 and Q4 2026, Respectively
THOMSON REUTERS  ·  08-12
Savara - Molbreevi MAAS Under Review by Ema and U.k's Mhra; Decisions Expected Q1 2027 and Q4 2026, Respectively
Savara announces EPO granted a patent covering formulation of Molbreevi
TIPRANKS  ·  07-30
Savara announces EPO granted a patent covering formulation of Molbreevi
Savara Says Europe, Australia Grant Molbreevi Liquid Formulation Patents Through 2041
Reuters  ·  07-30
Savara Says Europe, Australia Grant Molbreevi Liquid Formulation Patents Through 2041

Introduction

Company Name.
Savara Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
Issue price:
--